Key result
Magnesium supplementation may lower BP via calcium antagonism and endothelial improvement despite conflicting trial data.
Why the study?
HTN is highly prevalent with difficult patient compliance, motivating a review of the role and mechanisms of magnesium in reducing HTN to help inform its potential inclusion in mainstream antihypertensive regimens.
Does magnesium reduce hypertension and provide cardioprotection in humans?
Does magnesium reduce hypertension and provide cardioprotection in humans?
This review suggests magnesium has potential as an antihypertensive and cardioprotective agent, though current evidence remains mixed.
Hypertension (HTN) is a complex multifactorial disease that is one of the most prevalent disorders in our modern world. It can lead to fatal complications like coronary artery disease (CAD) and congestive heart failure (CHF) in high-risk individuals. The silent nature of HTN also contributes to its immense caseload and, today, with a number of combinations and various antihypertensive agents, patient compliance is becoming increasingly difficult. This article has reviewed the role and mechanisms of magnesium (Mg) in reducing HTN in the human body so as to provide more information that may help include it as a mainstream antihypertensive regimen. This review has also shed light on the cardioprotective nature of Mg against pathologies like CHF with special mention to patient groups who are at high risk for low Mg levels. Many studies included in this article solidify the former link, but some also provide contradicting data.
No takes yet. Share an insight, caveat, or question.
Patni et al. (2022) conducted a review in Hypertension. Magnesium was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: